Scintimun: Withdrawal of the marketing authorisation application



On 17 May 2006, CIS bio international has officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a marketing authorisation for SCINTIMUN, for diagnostic imaging to determine the location of infectious or inflammatory lesions and to detect metastases (when cancer spreads) in bone marrow.

  • List item

    Questions and answers on the withdrawal of the marketing application for Scintimun (PDF/44.2 KB)

    First published: 01/06/2006
    Last updated: 15/03/2010

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • besilesomab
    Active substance
    • besilesomab
    Date of withdrawal
    Company making the application
    CIS bio international
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating